The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival

Andrew J. Armstrong, Ian F. Tannock, Ronald de Wit, Daniel J. George, Mario Eisenberger, Susan Halabi

Research output: Contribution to journalArticlepeer-review

Abstract

Aims of the study: There are no known predictive factors of response in men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). We investigated pre-treatment factors that predicted a ≥30% PSA decline (30% PSAD) within 3 months of starting chemotherapy, and assessed performance of a risk group classification in predicting PSA declines and overall survival (OS) in men with mCRPC. Methods: In TAX327, 1006 men with mCRPC were randomized to receive docetaxel (D) in two schedules, or mitoxantrone (M), each with prednisone: 989 provided data on PSA decline within 3 months. Predictive factors for a 30% PSAD were identified using multivariable regression in D-treated men (n = 656) and validated in M-treated men (n = 333). Results: Four independent risk factors predicted 30% PSAD: pain, visceral metastases, anaemia and bone scan progression. Risk groups (good: 0-1 factors, intermediate: 2 factors and poor: 3-4 factors) were developed with median OS of 25.7, 18.7 and 12.8 months (p < 0.0001); 30% PSAD in 78%, 66% and 58% of men (p < 0.001); and measurable disease response in 19%, 9% and 5% of men (p = 0.018), respectively. In the validation cohort, similar predictive ability was noted for 30% PSAD, tumour response and OS. PCWG2 subtypes were also predictive but resulted in unequal grouping. C-indices were 0.59 and 0.62 for 30% PSAD and OS in the validation dataset, respectively. Conclusions: Risk groups have been identified and validated that predict PSAD and OS in men with mCRPC and may facilitate evaluation of new systemic regimens warranting definitive testing in comparison with docetaxel and prednisone. Prospective validation of this classification system is needed.

Original languageEnglish (US)
Pages (from-to)517-525
Number of pages9
JournalEuropean Journal of Cancer
Volume46
Issue number3
DOIs
StatePublished - Feb 2010

Keywords

  • Castration-resistant
  • Hormone-refractory
  • Metastatic
  • PSA response
  • Predictive factor
  • Prognostic factor
  • Prostate cancer
  • Risk groups
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival'. Together they form a unique fingerprint.

Cite this